EN | TR
E-ISSN: 3061-9947
Non-Hodgkin Lenfomalı Hastalarda Hepatit B ve C Virüs Seroprevalansı: Tek Merkez Deneyimi
PDF
Cite
Share
Request
VOLUME: 42 ISSUE: 1
P: 27-29
2009

Non-Hodgkin Lenfomalı Hastalarda Hepatit B ve C Virüs Seroprevalansı: Tek Merkez Deneyimi

Acta Haematol Oncol Turc 2009;42(1):27-29
Ülkü YALÇINTAŞ ARSLAN
Fatih Oğuz ÖNDER
Doğan UNCU
Saadet TOKLUOĞLU
Ayşe GÖK DURNALI
Gökhan ÇELENKOĞLU
Güngör UTKAN
Necati ALKIŞ
1. SB Dr. Abdurrahman Yurtarslan Ankara Onkoloji Eğtim ve Araştırma Hastanesi, Medikal Onkoloji Bölümü, ANKARA
2. Ankara Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Bilim Dalı, ANKARA
3.
No information available.
No information available
Received Date: 2014-08-28T17:06:34
PDF
Cite
Share
Request

Abstract

Hepatitis B and C viruses (HBV and HCV) are hepatotrophic viruses that can also proliferate in lymphoid tissues. Both of them can be cause chronic antigenic stimulation and may be related vvith lymphoproliferative disorders. Aim of this study is to evaluate HBV and HCV viruses seroprevalence in non-Hodgkin’s lymphoma (NHL) patients in our cancer çenter and their rela-tion vvith patient characteristics. We investigated hepatitis B virüs surface antigen (HbsAg) and anti-hepatitis C virüs antigen (anti-HCV-Ab) frequency in one hundred sixty four NHL patients retrospectively who admitted in our hospital betvveen November 2001- March 2008. We overvievved in the study HBV and HCV infected patients’ disease characteristics. HBsAg and anti-HCV-Ab tests had been applied by Enzyme-Linked İmmunosorbent Assay (ELISA) for these patients as a part of initial evaluating process at their first visit. The control group consisted of non-cancer patients treated in orthopedi clinics of our hospital (n= 165). Histologically confirmed 164 NHL patients vvere enrolled in this study. Among those 159 vvere B-cell lymphoma patients and the rest 5 vvere T-cell origin lymphoma patients. Tvventy three patients of 159 patients (14%) vvere diagnosed as low grade lymphoma. Ninety one patients (55%) vvere male and seventy three patients (45%) vvere female. HBsAg vvas found positive in fifteen patients (9.1%). Three patients had extranodai and nine patients had nodal diffuse large B-cell lymphoma (DLBCL). Rest of these patients had low grade iymhomas. Anti-HCV-Ab vvas positive in three (1.8%) patients, additionally HBsAg positivity vvas detected in the same three patients. One of them had splenic other two patients had diffuse large B-cell tymphomas. HBsAg prevalence vvas found higher but anti-HCV-Ab prevaience vvas found similar betvveen NHL and control group (9.1 vs 3%, p= 0.0366 and 1.8 vs 1.2%, p= 0.9945 respectiveiy). Ali of patients received chemotherapy except one patient at stage I follicular lymphoma who had HBsAg positive. Six patients infected HBV and/or HCV ıvere treated antiviral agents. Two patients among 15 who did not received prophylactic antiviral therapy during their cytotoxic treatment suffered from reactivation of HBV infection (%13) These findings supported that hepatitis carrier frequency in NHL patients more than non-cancer patients population according to our cancer çenter data. For these reason hepatits B and C markers should be evaluated before NHL treatment in our country.